Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Smallpox vaccinia vaccine is a **live viral vaccine** used for active immunization against smallpox and related orthopoxvirus exposure risk. It uses **vaccinia virus**, a poxvirus related to variola virus but less pathogenic in humans, to induce humoral and cellular immune responses that protect against smallpox. The term is **non-specific** because it can refer to multiple distinct products and generations, including replication-competent vaccinia vaccines such as ACAM2000 and older Dryvax, as well as replication-deficient Modified Vaccinia Ankara vaccines such as JYNNEOS, which differ in strain, manufacturing platform, administration, and safety profile. These vaccines have primarily been used for biodefense preparedness and vaccination of people at elevated occupational or exposure risk rather than for routine population-wide immunization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on smallpox vaccinia vaccine.